Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31633023.
- Also identified by DOI 10.1126/sciadv.aax2518 and PMC identifier 6785256.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The G protein-coupled cysteinyl leukotriene receptor CysLT<sub>1</sub>R mediates inflammatory processes and plays a major role in numerous disorders, including asthma, allergic rhinitis, cardiovascular disease, and cancer. Selective CysLT<sub>1</sub>R antagonists are widely prescribed as antiasthmatic drugs; however, these drugs demonstrate low effectiveness in some patients and exhibit a variety of side effects. To gain deeper understanding into the functional mechanisms of CysLTRs, we determined the crystal structures of CysLT<sub>1</sub>R bound to two chemically distinct antagonists, zafirlukast and pranlukast. The structures reveal unique ligand-binding modes and signaling mechanisms, including lateral ligand access to the orthosteric pocket between transmembrane helices TM4 and TM5, an atypical pattern of microswitches, and a distinct four-residue-coordinated sodium site. These results provide important insights and structural templates for rational discovery of safer and more effective drugs.
Medical subject headings
- Anti-Asthmatic Agents
- Receptors, Leukotriene